References
- Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007;370:1829-39
- Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
- Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. National Institute for Clinical Excellence. 2010. Available at: http://www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf [Last accessed January 2013]
- British Cardiac Society, British Hypertension Society, Diabetes U.K., Heart UK, Primary Care Cardiovascular Society, Association. S. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52
- The management of type 2 diabetes. National Institute for Health and Clinical Excellence. 2009. Available at: http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf [Last accessed March 2011]
- SIGN 97 risk estimation and the prevention of cardiovascular disease: a national clinical guideline. Scottish Intercollegiate Guidelines Network. 2007. Available at: http://www.sign.ac.uk/pdf/sign97.pdf [Last accessed February 2013]
- Identification and management of familial hypercholesterolaemia. National Institute for Clinical Excellence. 2008. Available at: http://www.nice.org.uk/nicemedia/pdf/CG071NICEGuideline.pdf [Last accessed December 2012]
- The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Preventive Cardiol 2012;19:585-667
- Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. National Institute for Clinical Excellence. 2007. Available at: http://guidance.nice.org.uk/TA132 [Last accessed December 2012]
- MeReC Extra No.47. National Prescribing Centre. 2010. Available at: http://www.npc.co.uk/merec/cardio/cdlipids/resources/merec_extra_no47.pdf [Last accessed December 2012]
- Bedfordshire and Hertfordshire Heart and Stroke Network, 2010. Ezetimibe: Place in therapy: recommendations from the Bedfordshire and Hertfordshire Heart and Stroke Network, NHS Bedford.
- Ezetimibe – limited place in therapy incorporating updated NHS Sefton lipid modification guidance. NHS Sefton. Available at: http://www.seftonpct.nhs.uk/your-health/medicines-management/Prescriber_updates.asp [Last accessed December 2012]
- Lipid Modification in Patients With High Risk of CVD. Wirral NHS Foundation Trust. 2009. Available at: http://www.wirral.nhs.uk/document_uploads/Disclosure-Jan2010/730LipidLoweringGuidelines.pdf [Last accessed March 2012]
- Money, money, money. Drug Therapeut Bull 2010;48:73
- Ezetimibe – an update. Drug Therapeut Bull 2009;47:91-5
- Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
- Use of NICE appraised medicines in the NHS in England – 2010 and 2011, experimental statistics. National Institute for Clinical Excellence. 2012. Available at: https://catalogue.ic.nhs.uk/publications/prescribing/primary/use-nice-app-med-nhs-exp-stat-eng-10-11/use-nice-app-med-nhs-exp-stat-eng-10-11-rep.pdf [Last accessed May 2013]
- NHS Centre for Coding and Classification. The READ Codes Version 3. London: Stationary Office, 1996
- Joint Formulary Committee. British National Formulary 60. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2010
- Joint Formulary Committee. British National Formulary 63. 2012. Available at: http://www.bnf.org/bnf/bnf/48// [Last accessed March 2012]
- Boggon R, Eaton S, Timmis A, et al. Current prescribing of statins and persistence to statins following ACS in the UK: a MINAP/GPRD study. Br J Cardiol 2012;19:24
- Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diabetes Care 2006;29:1220-6
- McGowan MP, for the Treating to New Target Study Group. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-5
- Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005;165:1147-52
- Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010;4:462-71
- Hippisley-Cox J, Coupland C. Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case–control analysis. Heart 2006;92:752-8
- Toth PP, Ballantyne CM, Davidson MH, et al. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. J Clin Lipidol 2012;6:180-91
- Aronow HD, Hess G, Hill J, et al. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol. Am J Therapeut 2010;17:167-75
- Rajagopalan S, Alemao E, Finch L, et al. Impact of new Joint British Societies’ (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr Med Res Opin 2007;23:2027-34